Dublin-based Avadel Pharmaceuticals plc has made a name for itself as a leading biopharmaceutical company operating in the United States. With a focus on enhancing patients' lives through innovative treatments, Avadel's flagship product offering is its LUMRYZ formulation - a sodium oxybate solution - currently undergoing Phase 3 clinical trials to curtail daytime sleepiness and cataplexy in adult narcolepsy patients. The firm was originally known as Flamel Technologies SA, having been founded in 2015, but rebranded as Avadel Pharmaceuticals plc in January 2017.